Read our Recent Headlines

April 23 Biotech Update

The sector has been struggling to say the least and when last I wrote, it was not clear to me the underlying cause, it is clear now (I will discuss.

April 17 Biotech Update

The trend in the sector is moving onto more and more shaky ground. Breaking below $86.22 on the XBI (the most recent low) would end the streak of higher highs.

April 16 Biotech Update

It was not the ideal start to the week but also not the worst. The selling from the morning opening was bad but we may have bottomed in the afternoon.

April 15 Biotech Update

Certainly an interesting start to the week. In terms of the broader sector, I suspect that we have a positive week as we are in the area where a bounce.

April 12 Biotech Update

The sector is certainly underperforming the broader markets and while that is frustrating, I do not see anything that is concerning. We did not get the breakout but if we.

April 11th Biotech Update

We are starting to get some news (from EASL) but still nothing that appears compelling for the sector. Sure, these are going to be potentially stock moving but it appears.

April 10th Biotech Update

Another slow day with the sector so far unable to do anything other than drift lower. I still see nothing to indicate a broader issue with the sector and this.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!